Geneva Advisors LLC raised its position in Grifols, S.A. (NASDAQ:GRFS) by 13.0% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 139,457 shares of the biotechnology company’s stock after buying an additional 16,076 shares during the period. Geneva Advisors LLC’s holdings in Grifols, were worth $2,947,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the company. William Blair Investment Management LLC acquired a new stake in shares of Grifols, during the second quarter worth $3,390,000. Blair William & Co. IL boosted its stake in shares of Grifols, by 25.0% in the second quarter. Blair William & Co. IL now owns 57,190 shares of the biotechnology company’s stock worth $1,208,000 after buying an additional 11,436 shares during the last quarter. Gamco Investors INC. ET AL boosted its stake in shares of Grifols, by 5.8% in the second quarter. Gamco Investors INC. ET AL now owns 31,750 shares of the biotechnology company’s stock worth $671,000 after buying an additional 1,750 shares during the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Grifols, during the second quarter worth $621,000. Finally, Comerica Bank boosted its stake in shares of Grifols, by 1.3% in the second quarter. Comerica Bank now owns 19,062 shares of the biotechnology company’s stock worth $389,000 after buying an additional 245 shares during the last quarter. Hedge funds and other institutional investors own 22.65% of the company’s stock.
Grifols, S.A. (GRFS) opened at 20.49 on Friday. The company has a 50-day moving average of $20.58 and a 200-day moving average of $19.95. Grifols, S.A. has a 1-year low of $14.27 and a 1-year high of $22.83. The firm has a market cap of $28.00 billion, a price-to-earnings ratio of 42.60 and a beta of 0.97.
ILLEGAL ACTIVITY WARNING: “Geneva Advisors LLC Raises Stake in Grifols, S.A. (GRFS)” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://stocknewstimes.com/2017/08/26/geneva-advisors-llc-raises-stake-in-grifols-s-a-grfs.html.
A number of brokerages recently weighed in on GRFS. BidaskClub cut shares of Grifols, from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Zacks Investment Research upgraded shares of Grifols, from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a report on Tuesday, July 4th. Bank of America Corporation reaffirmed a “buy” rating on shares of Grifols, in a research note on Tuesday, July 4th. Finally, Goldman Sachs Group, Inc. (The) lowered shares of Grifols, from a “buy” rating to a “neutral” rating in a research note on Friday, June 30th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Grifols, has a consensus rating of “Hold” and an average target price of $24.00.
About Grifols,
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.
